VYNE Therapeutics Inc. (VYNE) Social Stream
VYNE THERAPEUTICS INC (VYNE) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering VYNE.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-08-16 | 6 | $14 | $3 | $6.666 | $2.51 | 165.58% |
| 2021-11-11 | 6 | $14 | $3 | $7.2 | $2.51 | 186.85% |
| 2021-12-06 | 4 | $14 | $3 | $7.166 | $2.51 | 185.5% |
| 2022-03-21 | 6 | $14 | $3 | $7.166 | $2.51 | 185.5% |
| 2022-04-07 | 5 | $14 | $3 | $7.166 | $2.51 | 185.5% |
| 2022-05-18 | 5 | $10 | $3 | $5.8 | $2.51 | 131.08% |
| 2022-08-10 | 5 | $10 | $1.5 | $4.875 | $2.51 | 94.22% |
| 2022-08-15 | 5 | $5 | $1.5 | $3.625 | $2.51 | 44.42% |
| 2022-10-11 | 6 | $5 | $1.5 | $3.7 | $2.51 | 47.41% |
| 2022-11-11 | 5 | $89.928 | $26.978 | $69.694 | $2.51 | 2676.65% |
| 2023-03-10 | 5 | $89.93 | $26.978 | $69.694 | $2.51 | 2676.65% |
| 2023-03-14 | 4 | $89.93 | $28 | $58.965 | $2.51 | 2249.2% |
| 2023-05-12 | 3 | $71.941 | $9 | $36.313 | $2.51 | 1346.73% |
| 2023-08-15 | 4 | $71.941 | $9 | $36.313 | $2.51 | 1346.73% |
| 2023-09-26 | 4 | $28 | $5 | $14 | $2.51 | 457.77% |
| 2023-10-31 | 3 | $5.75 | $5 | $5.375 | $2.51 | 114.14% |
| 2023-11-13 | 3 | $6 | $5 | $5.583 | $2.51 | 122.43% |
The Trend in the Analyst Price Target
Over the past 35 months, VYNE's average price target has gone down $0.11.
VYNE reports an average of 1,088.73% for its upside potential over the past 35 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-03-10 | 5 | 89.930 | 26.978 | 69.694 | 2.610 | 2570.27% |
| 2023-03-14 | 5 | 89.930 | 28.000 | 69.950 | 2.410 | 2802.49% |
| 2023-08-15 | 4 | 71.941 | 9.000 | 36.313 | 4.850 | 648.72% |
| 2023-09-26 | 4 | 28.000 | 5.000 | 14.000 | 3.599 | 289% |
| 2023-11-10 | 3 | 6.000 | 5.000 | 5.583 | 3.510 | 59.06% |
VYNE Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1 | 3 | 0 | 0 | 0 | 0 | 3 |
The Trend in the Broker Recommendations
VYNE's average broker recommendation rating improved by 0 over the prior 26 weeks.
Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.
- To contextualize these metrics, consider that out of all US stocks, VYNE THERAPEUTICS INC's variance in analysts' estimates is lower than -1958.41% of them.
- VYNE has a higher upside potential (average analyst target price relative to current price) than 2115.94% of all US stocks.
- In the context of stocks in the small market cap category, VYNE THERAPEUTICS INC's average analyst price target is higher than 992.97% of them.
- To contextualize these metrics, consider that out of Healthcare stocks, VYNE THERAPEUTICS INC's number of analysts covering the stock is higher than 546.37% of them.
In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to VYNE THERAPEUTICS INC are CUE, ENSC, and NRXP.
View All Top Stocks by Price Target
Is VYNE a Buy, Hold or Sell? See the POWR Ratings now!